Natalie Berger, MD

Frontline antibody-drug conjugates boost progression-free survival in metastatic triple-negative breast cancer, showing early overall survival gains and expanding options.

New HER2+ breast cancer trials refine chemo and antibody use—cutting toxicity with de‑escalation, while escalating high‑risk patients with T‑DXd.

Natalie Berger, MD, weighed the biggest hurdles she witnesses in HPV vaccination and screening adherences.

See how breast cancer endocrine and targeted drugs inform endometrial and ovarian care—tamoxifen, CDK4/6 combos, and T-DXd.